HALEOS LABS LIMITED

BSE: HALEOSLABS540679ISIN INE320X01016

Healthcare
Pharmaceuticals

Share price

₹1,456.00+96.80 (+7.12%)

as of 2 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,778.35
52W low: ₹1,158.00
Off 52W high: -18.13%
1M return: -0.48%
3M return: -8.01%
6M return: -4.53%
1Y return: +21.35%
20D avg volume: 96
50 DMA: ₹1,507.74
200 DMA: ₹1,411.85

Key ratios Consolidated

Market cap: ₹440.19 Cr
Current price: ₹1,456.00
52W high / low: ₹1,778.35 / ₹1,158.00
Face value: ₹10.00
P/E: 28.85
P/B: 2.06
EPS (TTM): ₹50.47
Book value / share: ₹706.34
ROE: —
ROCE: 10.60%
Operating margin: —
Net margin: —
Debt / equity: 0.47
Net debt: ₹107.64 Cr
Interest cover: 4.91
Dividend yield: 0.10%
Dividend / share (TTM): ₹1.50
Payout: 2.97%
Cash conversion cycle: 87.3 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	72.94	75.14	94.78	81.37	82.50	89.11	84.60	78.46	92.55	89.99	72.05	69.26
	0.46	2.02	0.18	0.42	1.00	2.34	0.06	2.04	0.44	2.36	0.58	0.34
	73.41	77.15	94.97	81.79	83.50	91.45	84.66	80.50	92.99	92.35	72.64	69.60
	69.97	76.25	86.19	73.30	76.48	87.52	77.74	75.80	82.35	85.25	68.83	67.94
	40.14	35.86	44.74	39.83	28.41	32.74	39.43	35.02	42.72	33.47	39.19	35.75
	-13.68	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	17.55	16.17	16.70	16.23	16.29	16.47	14.60	14.09	14.38	12.74	12.56	12.28
	1.90	1.42	1.54	1.62	1.87	2.03	2.14	2.14	2.40	2.84	2.34	2.81
	4.24	3.85	3.91	3.89	3.82	3.80	3.76	3.76	3.68	3.78	3.73	3.73
	19.82	23.93	20.42	20.55	19.36	25.85	4.07	5.34	2.23	5.78	4.08	3.92
	3.44	0.91	8.78	8.49	7.02	3.93	6.92	4.70	10.64	7.10	3.81	1.66
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	3.44	0.91	8.78	8.49	7.02	3.93	6.92	4.70	10.64	7.10	3.81	1.66
	1.60	0.56	2.13	2.07	2.64	0.45	2.06	1.40	3.54	0.63	0.31	2.10
	1.84	0.34	6.65	6.43	4.38	3.48	4.85	3.30	7.10	6.47	4.12	-0.44
	8.75	1.44	21.89	20.19	13.75	9.83	18.08	15.46	23.15	19.53	14.24	2.20
Key metrics
	9.58	6.18	14.23	14.00	12.71	9.76	12.82	10.60	16.72	13.72	9.88	8.20
	13.10%	8.20%	15.00%	17.20%	15.40%	11.00%	15.20%	13.50%	18.10%	15.20%	13.70%	11.80%
	2.50%	0.50%	7.00%	7.90%	5.30%	3.90%	5.70%	4.20%	7.70%	7.20%	5.70%	-0.60%
	—	0.80%	—	4.00%	—	2.40%	—	—	—	—	—	—
	-11.60%	-15.70%	12.00%	3.70%	-10.90%	-1.00%	17.40%	13.30%	—	—	—	—
	-58.00%	-90.20%	37.10%	94.80%	-38.30%	-46.20%	17.70%	850.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	324.23	333.80	344.72	305.96	315.56	349.75
	3.08	2.43	4.86	3.83	3.07	2.07
	327.32	336.23	349.58	309.79	318.63	351.81
	305.71	311.03	323.39	299.94	304.39	331.77
	160.57	146.69	149.91	150.19	171.33	204.47
	-13.68	0.00	0.00	—	—	—
	66.65	65.38	59.54	49.27	43.43	39.90
	6.48	6.45	8.71	10.16	6.79	6.17
	15.89	15.47	15.00	14.94	10.79	10.01
	84.72	85.23	86.09	16.78	15.38	15.93
	21.62	25.20	26.19	9.85	14.24	20.04
	0.00	0.00	0.00	0.00	2.35	12.69
	21.62	25.20	26.19	9.85	16.59	32.73
	6.36	7.40	7.46	3.52	5.22	7.43
	15.26	17.80	18.73	6.33	11.38	25.28
	52.27	57.26	66.51	30.08	37.92	83.68
Key metrics
	43.99	47.12	49.90	34.95	34.17	48.91
	13.57%	14.10%	14.50%	11.40%	10.80%	14.00%
	4.71%	5.30%	5.40%	2.10%	3.60%	7.20%
	—	10.60%	14.10%	—	—	—
	-3.12%	-3.20%	12.70%	-3.00%	-9.80%	—
	-4.68%	-5.00%	195.90%	-44.40%	-55.00%	—
	—	-20.64	18.70	—	—	—
	—	2.09	1.82	—	—	—
	—	0.47	0.40	—	—	—
	—	107.64	83.52	—	—	—
	—	87.3	87.8	—	—	—
Balance sheet
	—	454.41	389.99	—	—	—
	—	163.11	150.57	—	—	—
	—	1.21	0.50	—	—	—
	—	61.34	68.79	—	—	—
	—	79.82	67.40	—	—	—
	—	17.77	12.65	—	—	—
	—	266.54	230.02	—	—	—
	—	61.41	53.27	—	—	—
	—	156.28	142.07	—	—	—
	—	108.85	84.02	—	—	—
	—	58.89	65.75	—	—	—
	—	49.96	18.27	—	—	—
	—	229.56	212.05	—	—	—
Cash flow
	—	37.22	34.05	—	—	—
	—	-57.90	-15.00	—	—	—
	—	21.38	-19.12	—	—	—
	—	57.86	15.35	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	67.83	63.38	80.72	77.84	79.04	85.43	82.88	78.50	86.57	86.37	71.23	67.84
	0.46	0.97	0.08	0.44	1.01	2.20	0.06	1.26	0.43	2.28	0.64	0.34
	68.29	64.35	80.80	78.28	80.05	87.63	82.94	79.75	87.00	88.65	71.87	68.17
	63.01	61.18	73.31	71.23	72.57	84.29	74.33	71.19	77.46	80.74	66.80	63.40
	37.28	33.02	39.36	41.60	33.64	38.95	43.14	37.60	44.75	37.51	42.71	37.25
	-7.83	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	13.25	12.06	12.46	12.38	12.49	12.46	11.24	10.90	11.18	9.55	9.70	9.57
	1.81	1.34	1.46	1.51	1.73	1.84	1.96	1.92	2.16	2.56	2.04	2.48
	3.01	2.66	2.69	2.68	2.63	2.62	2.56	2.57	2.50	2.62	2.55	2.55
	15.49	19.44	17.56	17.43	16.67	22.57	3.85	4.33	2.06	4.57	3.85	3.65
	5.28	3.18	7.49	7.05	7.48	3.33	8.61	8.56	9.54	7.91	5.07	4.78
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	5.28	3.18	7.49	7.05	7.48	3.33	8.61	8.56	9.54	7.91	5.07	4.78
	2.04	0.94	2.08	2.07	2.32	0.66	2.38	2.55	3.08	1.98	1.76	1.66
	3.24	2.23	5.41	4.98	5.16	2.68	6.23	6.01	6.46	5.93	3.31	3.12
	10.71	7.39	17.88	16.46	17.06	8.85	20.60	19.87	21.37	19.63	10.96	10.31
Key metrics
	10.10	7.18	11.64	11.24	11.84	7.79	13.13	13.05	14.20	13.09	9.66	9.81
	14.90%	11.30%	14.40%	14.40%	15.00%	9.10%	15.80%	16.60%	16.40%	15.20%	13.60%	14.50%
	4.80%	3.50%	6.70%	6.40%	6.50%	3.10%	7.50%	7.70%	7.50%	6.90%	4.60%	4.60%
	—	1.70%	—	3.60%	—	2.20%	—	—	—	—	—	—
	-14.20%	-25.80%	-2.60%	-0.80%	-8.70%	-1.10%	16.40%	15.70%	—	—	—	—
	-37.20%	-16.80%	-13.20%	-17.10%	-20.10%	-54.80%	88.20%	92.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	289.77	300.99	333.37	300.00	315.24	345.63
	1.95	1.42	3.95	3.84	2.88	1.54
	291.72	302.41	337.32	303.84	318.12	347.16
	268.73	277.22	307.28	284.73	302.10	326.88
	151.26	145.57	164.43	161.19	189.95	216.16
	-7.83	0.00	0.00	—	—	—
	50.15	49.39	45.78	37.94	34.72	32.51
	6.12	6.03	7.88	8.90	5.09	4.62
	11.04	10.66	10.26	10.25	8.17	7.99
	69.92	72.06	74.24	14.94	14.28	15.05
	23.00	25.19	30.04	19.11	16.02	20.29
	0.00	0.00	0.00	—	2.35	12.69
	23.00	25.19	30.04	19.11	18.37	32.98
	7.13	7.41	8.67	6.05	5.16	7.60
	15.86	17.78	21.37	13.06	13.22	25.38
	52.44	58.80	70.69	43.22	43.72	83.95
Key metrics
	40.16	41.88	48.18	38.26	31.63	45.59
	13.86%	13.90%	14.50%	12.80%	10.00%	13.20%
	5.47%	5.90%	6.40%	4.40%	4.20%	7.30%
	—	11.50%	16.20%	—	—	—
	-11.07%	-9.70%	11.10%	-4.80%	-8.80%	—
	-21.02%	-16.80%	63.60%	-1.20%	-47.90%	—
	—	-10.81	13.94	—	—	—
	—	2.16	1.31	—	—	—
	—	0.43	0.40	—	—	—
	—	92.71	78.77	—	—	—
	—	85.3	86.7	—	—	—
Balance sheet
	—	403.34	358.31	—	—	—
	—	181.71	177.79	—	—	—
	—	0.40	0.40	—	—	—
	—	54.26	64.53	—	—	—
	—	69.81	60.58	—	—	—
	—	54.54	51.27	—	—	—
	—	188.61	148.41	—	—	—
	—	53.79	45.98	—	—	—
	—	133.02	124.30	—	—	—
	—	93.11	79.17	—	—	—
	—	57.93	61.86	—	—	—
	—	35.18	17.31	—	—	—
	—	214.58	197.18	—	—	—
Cash flow
	—	38.43	28.03	—	—	—
	—	-49.28	-13.77	—	—	—
	—	10.85	-14.20	—	—	—
	—	49.24	14.09	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -1.53%
Sales CAGR 5Y: —
Profit CAGR 3Y: +10.38%
Profit CAGR 5Y: —
Sales YoY (TTM): -11.07%
Profit YoY (TTM): -21.02%

Consolidated

Sales CAGR 3Y: +1.89%
Sales CAGR 5Y: —
Profit CAGR 3Y: +16.08%
Profit CAGR 5Y: —
Sales YoY (TTM): -3.12%
Profit YoY (TTM): -4.68%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 72.09%

Holder	Type	Holding	Previous	Change
ANNAPURNA TALLURI	Promoter Group	24.56%	—	—
TVVSN MURTHY	Promoter	15.88%	—	—
VENKATA PRAVEEN TALLURI	Promoter Group	9.06%	—	—
RAMESH BABU POTLURI	Promoter	7.94%	—	—
SUDEEPTHI GOPINEEDI	Promoter Group	6.60%	—	—
HIMA BINDU POTLURI	Promoter Group	2.76%	—	—
TRILOK POTLURI	Promoter Group	2.58%	—	—
VAMSI KRISHNA POTLURI	Promoter Group	2.42%	—	—
HARITA PROJECTS PRIVATE	Public	1.76%	—	—
VIJAYAKUMAR S	Public	1.11%	—	—
POTLURI INFRA PROJECTS LLP	Promoter Group	0.26%	—	—
SUKUMARI KONERU	Promoter Group	0.02%	—	—
VENKATA CHAITANYA GOPINEEDI	Promoter Group	0.01%	—	—
POTLURI LABORATORIES PRIVATE LIMITED	Promoter Group	0.00%	—	—
RAJESWARA RAO GOPINEEDI	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
HALEOS LABS LIMITED	440	1,456.00	28.85	10.60%	-3.12% TTM	-4.68% TTM	+21.35%

Filings & corporate actions

Recent announcements

Dividend payable to shareholders who have not yet updated their KYC details is withheld and shall be released upon compliance with the KYC norms.31 Oct 2026 · Company Update / General
Enclosed -- RTA certificate.15 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Enclosed1 Oct 2026 · AGM/EGM / AGM
Enclosed30 Sep 2026 · AGM/EGM / AGM
Intimation of Closure of Trading Window.21 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Update on the material subsidiary of the Company.18 Sep 2026 · Company Update / General
Communication to physical shareholders providing them with the link to the Annual Report and AGM Notice.9 Sep 2026 · Company Update / General
Enclosed newspaper advertisement for the AGM Notice.8 Sep 2026 · Company Update / General
Enclosed - 20th AGM Notice.8 Sep 2026 · AGM/EGM / AGM
Enclosed Annual Report for the year ended 31st March, 2026.8 Sep 2026 · Others / Reg. 34 (1) Annual Report
The record date for the dividend (F26) and the 20th AGM will be Wednesday, September 23, 2026.5 Sep 2026 · Corp. Action / Record Date
Events calendar for the 20th Annual General Meeting.5 Sep 2026 · Company Update / General
Outcome of Postal Ballot.1 Sep 2026 · AGM/EGM / Postal Ballot
Outcome of Board meeting.1 Sep 2026 · AGM/EGM / Postal Ballot
Enclosed email communication sent to Shareholders.24 Aug 2026 · Company Update / General
Enclosed -- newspaper advertisement for Q1F27 results.7 Aug 2026 · Company Update / General
Mahi Drugs Private Limited appointed Cost Auditors for the year 2026-27 and Mr. Vincent P Asrao as Nominee Director.5 Aug 2026 · Company Update / General
Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam were reappointed for a second term of 5 years w.e.f. November 13, 2026, subject to approval of shareholders.5 Aug 2026 · Company Update / General
Enclosed - Outcome of 98th Board meeting.5 Aug 2026 · Board Meeting / Outcome of Board Meeting
Haleos Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve the unaudited financial results ....1 Aug 2026 · Board Meeting / Board Meeting
Enclosed - Newspaper advertisement.30 Jul 2026 · Company Update / General
Postal Ballot Notice (30.07.2026 to 28.08.2026)29 Jul 2026 · AGM/EGM / Postal Ballot
Enclosed: events calendar for the Postal Ballot.29 Jul 2026 · Company Update / General
Enclosed -- RTA certificate.7 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window.18 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Communication to shareholders regarding transfer of shares to the IEPF suspense account for the unclaimed dividend for the year 2018-19.16 Jun 2026 · Company Update / General
In lieu of change in Board composition, the Board Committees are reconstituted.2 Jun 2026 · Company Update / General
Enclosed - newspaper advertisement for Q4 results.2 Jun 2026 · Company Update / General
Enclosed financial results for the quarter and year ended 31st March, 2026.30 May 2026 · Result / Financial Results
Enclosed - Annual Secretarial Compliance Report F2630 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Reappointment of Mrs Sudeepthi Gopineedi as whole-time Director for a further period of 5 years w.e.f. Sept 2, 2026, subject to approval of Shareholders.29 May 2026 · Company Update / Change in Management
Enclosed are the details related to the appointment of Statutory Auditors and Cost Auditors.29 May 2026 · Company Update / General
Resignation of Mrs. Sundaramma Patilbandla from the post of Independent Director w.e.f. May 29, 2026.29 May 2026 · Company Update / Resignation of Director
Enclosed - Outcome of 97th Board meeting.29 May 2026 · Board Meeting / Outcome of Board Meeting
Request shareholders to update their KYC details (reminder no. 6) and information about the second 100-day campaign from April 1, 2026 to July 9, 2026.25 May 2026 · Company Update / General
Haleos Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the audited financial results (Standalone ....22 May 2026 · Board Meeting / Board Meeting
Credit rating of the Company and its material subsidiary.22 May 2026 · Company Update / Credit Rating
Outcome along with Scrutinizers report.1 May 2026 · AGM/EGM / Postal Ballot
Disclosure related to the non-encumbrance of shares received from promoters.8 Apr 2026 · Company Update / General
Enclosed - RTA certificate.8 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.5000	23 Sep 2026	23 Sep 2026	—
Dividend - Rs. - 1.5000	24 Sep 2025	24 Sep 2025	—
Dividend - Rs. - 1.5000	23 Sep 2024	—	—

Board meetings

5 Aug 2026 Board Meeting - Financial Results